Fatal and non-fatal adverse events of glucocorticoid therapy for Graves' orbitopathy: A questionnaire survey among members of the European Thyroid Association

European Journal of Endocrinology

Volumn 166, Issue 2, 2012, Pages 247-253

  Marcocci, Claudio ^a   Watt, Torquil ^b   Altea, Maria Antonietta ^a   Rasmussen, Ase Krogh ^b   Feldt Rasmussen, Ulla ^b   Orgiazzi, Jacques ^c   Bartalena, Luigi ^d  

^a UNIVERSITY OF PISA   (Italy)

^b University of Copenhagen   (Denmark)

^c UNIVERSITÉ LYON 1   (France)

^d UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE; PREDNISONE;

ACUTE LIVER FAILURE; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL PRACTICE; CONTROLLED STUDY; CUSHINGOID SYNDROME; DEPRESSION; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG EFFECT; DRUG FATALITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENCEPHALITIS; ENDOCRINE OPHTHALMOPATHY; FEMALE; HEALTH SURVEY; HEPATITIS; HUMAN; HYPERGLYCEMIA; LIVER DISEASE; LUNG EMBOLISM; MULTIPLE CYCLE TREATMENT; PATIENT ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; WEIGHT GAIN;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; COMMITTEE MEMBERSHIP; DATA COLLECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; ENDOCRINOLOGY; EUROPE; FEMALE; GLUCOCORTICOIDS; GRAVES OPHTHALMOPATHY; HUMANS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES; SOCIETIES, MEDICAL; THYROID GLAND; YOUNG ADULT;

EID: 84856100099     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-0779     Document Type: Article

References (24)

1. Bartalena L, Baldeschi L, Dickinson AJ, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits MP, Perros P, Boboridis K, Boschi A, Currò N, Daumerie C, Kahaly GJ, Krassas G, Lane CM, Lazarus JH, Marinò M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G & Wiersinga WM. Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy. European Journal of Endocrinology 2008 158 273-285. (doi:10.1530/EJE-07-0666)
2. Marcocci C, Bartalena L, Tanda ML, Manetti L, Dell'Unto E, Rocchi R, Barbesino G, Mazzi B, Bartolomei MP, Lepri P, Cartei F, Nardi M & Pinchera A. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. Journal of Clinical Endocrinology and Metabolism 2001 86 3562-3567. (doi:10.1210/jc.86.8.3562)
3. Macchia PE, Bagattini M, Lupoli G, Vitale M, Vitale G & Fenzi G. High-dose intravenous corticosteroid therapy for Graves' ophthalmopathy. Journal of Endocrinological Investigation 2001 24 152-158. (Pubitemid 32293637)
4. Kauppinen-Makelin R, Karma A, Leinonen E, Loyttyniemi E, Salonen O, Sane T, Setala K, Viikari J, Heufelder A & Valimaki M. High dose intravenous methylprednisolone pulse therapy versus oral prednisone for thyroid-associated ophthalmopathy. Acta Ophthalmologica Scandinavica 2002 80 316-321. (doi:10.1034/j.1600-0420.2002.800316.x)
5. Kahaly GJ, Pitz S, Hommel G & Dittmar M. Randomized, single blind trial of intravenous versus oral glucocorticoid monotherapy in Graves' orbitopathy. Journal of Clinical Endocrinology and Metabolism 2005 90 5234-5240. (doi:10.1210/jc.2005-0148)
6. Aktaran S, Akarsu E, Erbagci I, Araz M, Okumus S & Kartal M. Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves' ophthalmopathy. International Journal of Clinical Practice 2007 61 45-51. (doi:10.1111/j.1742-1241.2006.01004.x)
7. Stiebel-Kalish H, Robenshtok E, Hasanreisoglu M, Ezrachi D, Shimon I & Leibovici L. Treatment modalities for Graves' ophthalmopathy: systematic review and metaanalysis. Journal of Clinical Endocrinology and Metabolism 2009 94 2708-2716. (doi:10.1210/jc.2009-0376)
8. Zang S, Ponto KA & Kahaly GJ. Clinical review: intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity. Journal of Clinical Endocrinology and Metabolism 2011 96 320-332. (doi:10.1210/jc.2010- 1962)
9. Weissel M & Hauff W. Fatal liver failure after high-dose glucocorticoid pulse therapy in a patient with severe thyroid eye disease. Thyroid 2000 10 521. (Pubitemid 30437157)
10. Marinó M, Morabito E, Brunetto MR, Bartalena L, Pinchera A &Marocci C. Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy. Thyroid 2004 14 403-406. (doi:10.1089/105072504774193276)
11. Lendorf ME, Rasmussen AK, Fledelius HC & Feldt-Rasmussen U. Cardiovascular and cerebrovascular events in temporal relationship to intravenous glucocorticoid pulse therapy in patients with severe endocrine ophthalmopathy. Thyroid 2009 19 1431-1432. (doi:10.1089/thy.2009.0069)
12. Gursoy A, Cesur M, Erdogan MF, Corapcioglu D & Kamel N. New-onset acute heart failure after intravenous glucocorticoid pulse therapy in a patient with Graves' ophthalmopathy. Endocrine 2006 29 513-516. (doi:10.1385/ENDO:29:3: 513)
13. Owecki M & Sowiński J. Acute myocardial infarction during high-dose methylprednisolone therapy for Graves' ophthalmopathy. Pharmacy World Science 2006 28 73-75. (doi:10.1007/s11096-006-9013-y)
14. SAS Institute, Inc. SAS/STAT® 9.1 User's Guide. Cary, NC: SAS Institute, Inc., 2004.
15. Marinò M, Morabito E, Altea MA, Ambrogini E, Oliveri F, Brunetto MR, Pollina LE, Campani D, Vitti P, Bartalena L, Pincheral A & Marcocci C. Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves' ophthalmopathy treated successfully with glucocorticoids themselves. Journal of Endocrinological Investigation 2005 28 280-284. (Pubitemid 43162778)
16. Kulig G, Kaźmierczyk-Puchalska A, Krzyzanowska-Swiniarska B &Pilarska K. Complications during systemic corticosteroid therapy combined with orbital radiotherapy in patients with Graves orbitopathy. Przeglȩd Lekarski 2004 61 855-856.
17. Le Moli R, Baldeschi L, Saeed P, Regensburg N, Moutits MP &Wiersinga WM. Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves' ophthalmopathy. Thyroid 2007 17 357-362. (doi:10.1089/thy.2006.0267)
18. Salvi M, Vannucchi G, Sbrozzi F, Del Castello AB, Carnevali A, Fargion S & Beck-Peccoz P. Onset of autoimmune hepatitis during intravenous steroid therapy for thyroid-associated ophthalmopathy in a patient with Hashimoto's thyroiditis: case report. Thyroid 2004 14 631-634. (doi:10.1089/ 1050725041692927)
19. Guillen EL, Martinez Ruiz A & Vidal Bugallo JB. Hypotension, bradycardia, and asystole after high-dose intravenous methylprednisolone in a monitored patient. American Journal of Kidney Diseases 1998 32 E4. (doi:10.1053/ajkd.1998.v32.pm10074612)
20. Erstad BL. Severe cardiovascular adverse effects in association with acute, high-dose corticosteroid administration. DICP: the Annals of Pharmacotherapy 1989 23 1019-1023. (Pubitemid 20019839)
21. Wollheim FA. Acute and long-term complications of corticosteroid pulse therapy. Scandinavian Journal of Rheumatology 1984 54 27-32. (doi:10.3109/03009748409103858)
22. Bocanegra TS, Castañeda MO, Espinoza LR, Vasey FB &Germain BF. Sudden death after methylprednisolone pulse therapy. Annals of Internal Medicine 1981 95 122. (Pubitemid 11079038)
23. Bartalena L & Tanda ML. Clinical practice. Graves' ophthalmopathy. New England Journal of Medicine 2009 360 994-1001. (doi:10.1056/NEJMcp0806317)
24. Bartalena L. What to do for moderate-to-severe and active Graves' orbitopathy if glucocorticoids fail? Clinical Endocrinology 2010 73 149-152. (doi:10.1111/j.1365-2265.2010.03783.x)